JP Morgan Chase’s Grace Therapeutics GRCE Stock Holding History

JP Morgan Chase’s Portfolio GRCE Stock Details GRCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-15	Closed	-$34	–	7803
2025 Q1	$34	Sell	15 -2	-12%	-$6	﹤0.01%	7043
2024 Q4	$65	Hold	17	–	–	﹤0.01%	7079
2024 Q3	$51	Buy	17 +15	+750%	+$40	﹤0.01%	7120
2024 Q2	$6	Buy	+2	New	+$6	﹤0.01%	7239
2023 Q4	–	Sell	-3,358	Closed	-$9.2K	–	7935
2023 Q3	$9.2K	Buy	+3,358	New	+$7.96K	﹤0.01%	6278
2023 Q2	–	Sell	-208	Closed	-$1K	–	7399
2023 Q1	$1K	Buy	+208	New	+$743	﹤0.01%	6563

Other funds holding GRCE

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

PWM

Palumbo Wealth Management Great Neck, New York $410M AUM 32.56% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MFA

Millington Financial Advisors Naperville, Illinois $237M AUM 22.22% 1-Year Est. Return

JP Morgan Chase's GRCE Position: Q2 2025 in Review

JP Morgan Chase sold out of Grace Therapeutics (GRCE) in Q2 2025, closing a stake of 15 shares — an estimated $34 sold.

JP Morgan Chase first reported a position in GRCE in Q1 2023 and held it in 6 quarters. The position peaked at $9.2K in Q3 2023. 20 funds tracked by Wall St. Rank hold GRCE as of Q2 2025.

JP Morgan Chase reported no remaining Grace Therapeutics position as of Q2 2025 after selling out during the quarter.
JP Morgan Chase sold 15 Grace Therapeutics shares in Q2 2025, an estimated $34.
JP Morgan Chase first reported a position in Grace Therapeutics in Q1 2023 and held it in 6 quarters.
JP Morgan Chase's Grace Therapeutics position peaked at $9.2K in Q3 2023.
20 funds tracked by Wall St. Rank held Grace Therapeutics as of Q2 2025.

Based on JP Morgan Chase's 13F filing for Q2 2025, filed 12 Aug 2025.